Lisata, GATC announces strategic alliance to advance AI-driven drug discovery

Lisata Therapeutics (LSTA) and GATC Health, GATC, announced a strategic alliance designed to accelerate and improve the success rate of the traditional drug development process. This collaboration builds on the foundation of earlier work performed by GATC for Lisata, in which GATC provided AI-derived analysis in support of Lisata’s certepetide drug candidate. Under the expanded relationship, Lisata will enhance its therapeutic pipeline by leveraging GATC’s proprietary Multiomics Advanced Technology platform to identify new AI-predicted combination therapies across all therapeutic areas. This approach not only opens the door to new treatment possibilities but also ensures that any resulting intellectual property will be derisked by the MAT analysis, providing predictions of safety, efficacy and side effects with a high degree of certainty.